National Institute of Allergy and Infectious Diseases (NIAID)
This study is to test an experimental HIV Vaccine. About 12 participants, aged 18-55 years and who already have cytomegalovirus (CMV) will take part in this study. Participants will come to the clinic for scheduled visits about 21 times over 12 months.
Inclusion Criteria: 1. At least 18 years old at screening and up to 55 years old on day of enrollment. 2. Access to a participating clinical research site and willingness to be followed for the planned duration of the study. 3. Demonstrates an understanding of the study and is able and willing to provide informed consent. 4. Agrees not to enroll in another study of an investigational agent during participation in the trial. 5. In good general health according to the clinical judgment of the site investigator. 6. Physical examination and laboratory results without clinically significant findin…
Treatment 1 (T1): VIR-1388, 6.9 × 10\^7 ffu to be administered as three 1 mL subcutaneous (SC) injections (total dose = 3 mL) at week 0 (month 0) and week 12 (month 3).
Control 1 (C1): Placebo for VIR-1388 \[HT Diluent Placebo\] to be administered as three 1 mL SC injections (total dose = 3 mL) at week 0 (month 0) and week 12 (month 3).
Arctuva estimate
Verify or correct the compensation shown for this listing.